Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08)Roger von Moos, Kathrin Zaugg, Pu Yan et al.|European Journal of Cancer|2017Cited by 27
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.Christoph Rochlitz, Ralph C. Winterhalder, Roger von Moos et al.|Journal of Clinical Oncology|2014Cited by 14
Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08.Roger von Moos, Kathrin Zaugg, Dieter Koeberle et al.|Journal of Clinical Oncology|2014Cited by 5
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras-unmutated, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07).Daniel Helbling, Dieter Koeberle, G. Bodoky et al.|Journal of Clinical Oncology|2011Cited by 4
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).Daniel Helbling, Dieter Koeberle, G. Bodoky et al.|Journal of Clinical Oncology|2015Cited by 0